Abstract-We recently showed that the transient expression of a hemagglutinin (HA) epitope-tagged, constitutively active mutant of the G protein ␣ q subunit (HA␣ q *) in the hearts of transgenic mice is sufficient to induce cardiac hypertrophy and dilatation that continue to progress after HA␣ q * protein becomes undetectable. We demonstrated that the activity of phospholipase C␤, the immediate downstream target of activated G␣ q , is increased at 2 weeks, when HA␣ q * is expressed, but also at 10 weeks, when HA␣ q * is no longer detectable. This observation suggested that the transient HA␣ q * expression causes multiple, persistent changes in cellular signaling pathways. We now demonstrate changes in the level, activity, or both of several signaling components, including changes in the amount and hormone responsiveness of phospholipase C␤ enzymes, in the basal level of diacylglycerol (which predominantly reflects activation of phospholipase D), in the amount or distribution of protein kinase C (PKC) isoforms (PKC␣, PKC␦, and PKC⑀), and in the amount of several endogenous G proteins. These changes vary depending on the isoform of the signaling molecule, the chamber in which it is expressed, and the presence or absence of HA␣ q *. Our results suggest that a network of linked signaling functions determines the development of hypertrophy. They also suggest that atria and ventricles represent different signaling domains. It is likely that such changes occur in other model systems in which the activity of a single signaling component is increased, either due to an activating mutation or due to overexpression of the wild type. (Circ Res. 1999;85:1085-1091.)
T he activation of signal transduction pathways mediated by heterotrimeric G q protein can lead to cardiac hypertrophy and dilatation (for a review, see Dorn and Brown 1 ). To understand better the cellular and molecular events leading to hypertrophy, several transgenic mouse models have been created with cardiac overexpression of various components of the G q -mediated signaling pathway, such as receptors that work through G q (eg, ␣-adrenoreceptors 2,3 and angiotensin receptors 4 ), G q protein ␣ subunits (wild type 5 or activated 6 ), and potential downstream targets (eg, protein kinase C␤ [PKC␤], 7, 8 calcineurin, and nuclear factor of activated T cells [NFAT] 9 ). Except for the mice expressing angiotensin receptors, which died shortly after birth, mice from the other lines developed cardiac hypertrophy, some with dilatation.
One objective in the production of transgenic animals that express single components of the transmembrane signaling machinery is to establish systems that will eventually allow the activity of the transgenic protein to be connected to the final phenotype. To achieve this goal, it is first essential to distinguish changes that arise directly in response to the activity of the transgenic protein from changes that arise due to secondary alterations in the activity or expression of other signaling components. So far, there has been no systematic attempt to characterize changes in signaling components that occur as a consequence of cardiac expression of G␣ q -coupled receptors, [2] [3] [4] wild-type G␣ q , 5 or putative downstream targets in the pathway. [7] [8] [9] The transgenic mouse line that we recently developed 6 makes an excellent model system in which to analyze primary changes due to expression of the transgenic protein versus secondary ones. This mouse line transiently expresses activated hemagglutinin (HA) epitope-tagged G protein ␣ q (HA␣ q *). The protein is present at 2 weeks, diminishes by 4 weeks, and is undetectable by 10 weeks. 6 The mice develop cardiac hypertrophy and dilatation that progress inexorably to death from heart failure between 8 to 30 weeks of age. We previously showed that the basal activity of phospholipase C (PLC␤, the direct target of activated ␣ q ) remains elevated at 10 weeks even though HA␣ q * becomes undetectable. 6 We now test the hypothesis that the transient expression of HA␣ q * leads to multiple, persistent secondary changes in many signaling components that continue after the HA␣ q * protein is downregulated and that may perpetuate the pathology. In a comparison of younger mice expressing HA␣ q * with older mice with undetectable HA␣ q *, we found changes in the amount, activity, or both of several signaling components, including the amount of PLC enzyme, its hormone responsiveness, the level of diacylglycerol (DAG), the amount and distribution of PKC, and the amounts of several endogenous G proteins.
Our work also shows that atria and ventricles, both of which are severely hypertrophied and dilated, are quite different in their response to the expression of HA␣ q *. Despite the fact that the ␣-myosin heavy chain promoter, which we used and which is widely used for cardiac-specific transgene expression, is active in all chambers of the heart, 10 there is little information so far about the biochemical consequences of overexpression of signaling components in the atria. Our data documenting differences between atria and ventricles and, in some cases, differences between right and left chambers suggest that the right and left sides of the heart, as well as the atria and ventricles, reflect not only distinct transcriptional domains 11 but also distinct signaling domains.
Materials and Methods

Production of HA␣ q * Transgenic Mice
Two transgenic mouse lines (␣ q *52 and ␣ q *44) were generated as previously described. 6 A homozygous line, called ␣ q *44h, was developed from ␣ q *44. These animals begin to reexpress atrial natriuretic factor and ␤-myosin heavy chain at 4 to 6 months and develop enlarged hearts by 14 months, confirming in a second line that the expression of HA␣ q * causes cardiac hypertrophy. In this study, we used heterozygous ␣ q *52 mice at 14 to 16 days (2 weeks) and 62 to 75 days (10 weeks) of age. The cardiac morphology of this line was previously described. 6 
Western Blot Analysis
Particulate and soluble protein fractions from atrial appendages, ventricles, and ventricular myocytes 12 from 2-and 10-week-old transgenic mice and littermate wild-type controls were prepared, separated on 9% SDS-PAGE, and blotted. 6 (The left and right atrial appendages were used in the present study and are referred to as left and right atria.) The left and right atria from 8 to 10 wild-type or transgenic 2-week-old mice were pooled; only right atria were used from 10-week-old mice (8 wild-type mice and 2 or 3 transgenic mice in each pool). Nitrocellulose membranes were cut into 5 strips to detect proteins of different molecular weights in the same samples on the same blot (the antibodies that were used are described in detail in the supplemental online information). The total amount of each PKC and PLC␤ isoform was calculated by multiplying the integrated signal obtained from an equal amount of the particulate and soluble proteins by the total protein in the particulate and soluble fractions. Similarly, the total amount of G protein subunits was calculated by taking into account the total amount of particulate protein.
Adenylyl Cyclase Activity
Two pools each of right atrial tissue from 10-week-old wild-type and transgenic mice (each containing a total of 15 to 20 mg tissue from 6 wild-type or 2 or 3 transgenic animals) were homogenized and ultracentrifuged at 100 000g. The adenylyl cyclase (AC) activity was determined in the particulate fraction as previously described. 13 
Measurement of [ 3 H]Inositol Phosphate Formation
Total inositol phosphate formation was measured in small pieces of atrial and ventricular tissue 6 that had been incubated for 30 minutes with or without carbamylcholine or endothelin-1.
DAG Levels
Lipid fractions were extracted from 15 to 25 mg atrial or 30 to 60 mg ventricular snap-frozen tissue according to the method of Bligh and Dyer 14 with minor modifications as described in the manufacturer's instructions for the s,n-1,2-DAG Assay Reagent System (Amersham Life Science). At 2 weeks, the right and left atria from 5 or 6 wild-type or transgenic mice were pooled. At 10 weeks, left atrial tissue that had been carefully freed of any blood and thrombi was used (each pool contained left atria from 6 wild-type mice or 2 transgenic mice). The radioactivity comigrating with a phosphatidic acid signal from the DAG standard was quantified by computerized densitometry. It was normalized to the signal obtained for the internal standard included in each sample. After blank subtraction, the data were normalized to milligrams of protein in each homogenized sample before extraction and referred to the age-matched wild-type control.
Statistical Analysis
Data are reported as meanϮSEM (for n determinations). Comparisons between transgenic mice and wild-type controls were made with the use of unpaired two-tailed Student t test. PϽ0.05 was considered significant. An expanded Materials and Methods section is available online at http://www.circresaha.org.
Results and Discussion
Transient cardiac expression of activated HA␣ q * leads to hypertrophy and dilatation. 6 HA␣ q * protein is expressed at 2 weeks, when the hearts are morphologically barely distinguishable from wild type, but is not detectable at 10 weeks, when they are dilated and hypertrophied. The primary target of activated ␣ q is activation of PLC␤. We have previously shown that PLC activity is elevated, both when HA␣ q * is expressed and after the protein becomes undetectable. 6 This observation suggests that transient HA␣ q * expression causes persistent changes in cellular signaling pathways. We now show that the persistent changes involve not only the activity but also the cellular levels of several signaling proteins. The mechanism by which the proteins are changed is not yet known but may involve differences in transcription of the gene, stability of the protein, or both. A striking finding in our study is that atria and ventricles respond very differently to the initial expression of the HA␣ q * protein. At 2 weeks, the levels of HA␣ q * expression are similar in atria and ventricles, 6 although in atria the protein has been expressed throughout development, whereas in ventricles, it is turned on shortly after birth. 10 Despite the fact that activated HA␣ q * has been expressed throughout development, at 2 weeks, the biochemical changes in the atrium are modest and generally similar to those in ventricle. This finding suggests that the long-term consequences of HA␣ q * expression depend not only on the immediate effects of the protein itself and the signaling pathways that it sets in motion but also on the different hemodynamic stresses on atria and ventricles.
Expression of G Protein ␣ and ␤ Subunits
To interpret any changes in downstream effectors, it is essential to know whether the expression of HA␣ q * causes changes in the endogenous G protein subunits. We demonstrated previously that at 10 weeks, when HA␣ q * is no longer detectable, the level of endogenous ␣ q * is upregulated (Reference 6, see also Figure 1 ). We now demonstrate that the levels of other G proteins also change and that these changes occur in a chamber-and an isoform-specific fashion ( Figure  1 ). At 2 weeks, the amount of the various G protein subunits tested with Western blotting was only slightly different from that of age-matched wild-type littermate controls in both atria and ventricles from ␣ q *52 mice ( Figure 1A and 1B, respectively). At 10 weeks, the ventricular levels of some G protein subunits were modestly increased further. In contrast, in the right atrium, there was a substantial increase in ␣ q/11 (2.9-fold), ␣ i (2.7-fold), and the long form of ␣ s (4.8-fold) compared with wild-type controls ( Figure 1A ). The short form of ␣ s was unchanged compared with the wild type, indicating that the ␣ s isoforms are differentially regulated. A similar observation, albeit much less pronounced, was made in 10-week-old ventricles in which the long form of ␣ s was slightly increased, whereas the short form was slightly decreased ( Figure 1B) . In both atria and ventricles, the relative rise in ␣ subunits exceeded the relative rise in G protein ␤␥ subunits. However, because the absolute levels of the ␣ subunits in mouse heart are not known, one cannot conclude from these data that the ␣ subunits are in excess of the ␤␥ subunits. A large fractional increase in a very nonabundant ␣ subunit could lead to a small change in relative ␤␥ subunit levels.
It was not possible to obtain sufficient atrial myocytes for biochemical studies, but we isolated ventricular myocytes and observed qualitatively similar changes in the level of G protein ␣ q/11 (data not shown). This suggests that the changes in expression levels that we observed reflect changes in the myocytes (see also later discussion of PKC expression). However, additional changes in nonmyocytes cannot be ruled out.
To determine whether the pronounced rise in G␣ s subunit levels in the right atria of 10-week-old ␣ q *52 mice has any functional consequence, we measured the activity of the enzyme regulated by G s , AC. There was no significant difference in basal AC activity or in the response to stimulation with the nonhydrolyzable GTP analog guanosine-5Ј-O-(3-thio)triphosphate, the ␤-adrenergic agonist isoproterenol, or the diterpene forskolin, which directly activates the catalytic units of AC synergistically with G protein ␣ s , 15 in right atrial membranes from 10-week-old ␣ q *52 mice compared with wild-type controls ( Table 1 ). The lack of enhanced AC activation despite a pronounced increase in the long form of ␣ s may be explained by the concomitant rise in G protein ␣ i subunits (see earlier), which exert an inhibitory effect on AC activity. Alternatively, because the major AC isoforms expressed in the heart, AC V and VI, are sensitive to direct inhibition through Ca 2ϩ (for a review, see Taussig and Gilman 16 ), a rise in Ca 2ϩ in response to chronic PLC activation (see below) could counteract a potential rise in AC activity. Other explanations are also possible.
Expression of PLC␤ Isoforms
In our previous study, we showed that although HA␣ q * is undetectable at 10 weeks, the basal PLC activity continues to Chamber-specific changes in G protein expression in hearts of ␣ q *52 mice. Total amount of G protein ␣ and ␤ subunits in particulate fraction of atria (A) and ventricles (B) from 2-and 10-week-old ␣ q *52 mice. Except for trace amounts of ␣ s (no difference between ␣ q *52 and wild type), none of the other G protein subunits tested were found in soluble fraction. For ␣ q/11 , results obtained with antibody 3A-180 are shown. A different antibody against ␣ q/11 gave qualitatively similar results. Tissue from both sides of heart was always combined except for 10-week-old atria (right atria only). Data represent meanϮSEM from 2 to 4 atrial pools and 4 to 6 ventricles and are expressed in percent of age-matched wild-type controls. Variation in wildtype samples was Ϯ3% to 10% for ventricular samples (4 wildtype mice for each time point) and Ϯ4% to 15% for atrial pools (nϭ2) (data not shown). *PϽ0.05 (Student t test) relative to agematched wild type. #No statistical test was performed for comparison between 2 atrial pools from 2-week-old ␣ q *52 and wildtype mice. 
121Ϯ9 (5) 134Ϯ15 (5) Forskolin (100 mol/L) 327Ϯ60 (5) 386Ϯ53 (5) GTP␥S indicates guanosine-5Ј-O-(3-thio)triphosphate. AC activity was determined under basal conditions and in response to stimulation with GTP␥S (1 mol/L), isoproterenol (10 mol/L), and forskolin (100 mol/L). Each atrial pool was assayed in duplicate in 2 or 3 independent experiments. There was no statistically significant difference between ␣ q ‫25ء‬ mice and wild-type mice for any of the conditions tested.
Values given in meanϮSEM pmol cAMP/min per mg protein.
be elevated. 6 This continued elevation may be in part due to the secondary rise in endogenous ␣ q (Figure 1) . We now show that in addition, the level of PLC␤ enzyme itself is relatively higher. We find that the amount of PLC␤ 1 and PLC␤ 3 decreases as the animals age (Figure 2A and 2B). PLC␤ 2 is not expressed in the heart. 17 In 10-week-old wild-type mice, the levels of both PLC␤ isoforms were decreased by 30% to 65% compared with the levels at 2 weeks. However, in the atria of ␣ q *52 mice, there was no maturational drop in PLC␤ 1 or PLC␤ 3 ( Figure 2A) . Thus, the total amount of PLC␤ in atria from 10-week-old ␣ q *52 mice was increased compared with that in wild-type controls. In ventricles, only the decline in PLC␤ 1 was blunted ( Figure 2B ), so the difference between wild types and ␣ q *52 was less in ventricles than in atria. There was no significant change in the distribution of PLC␤ 1 or PLC␤ 3 between particulate and soluble fractions (data not shown).
Agonist Activation of PLC
Constitutively active G protein ␣ subunits activate downstream effectors but interact poorly with receptors and with G protein ␤␥ subunits. Therefore, the overexpression of HA␣ q * should not affect the endogenous response to receptor activation. Unless the level of effector is limiting, we expect hormonal stimulation of PLC␤ in 2-week-old ␣ q *52 mice to be additive to the elevated basal activity, with no net difference between wild-type and ␣ q *52 mice. However, if the levels of other signaling components are changed as a consequence of activated HA␣ q * expression, then the increment in effector activity due to receptor activation may differ between wild-type and ␣ q *52 mice. We hypothesized that the agonist-stimulated increment in PLC activity would be additive to the elevated basal activity at 2 weeks, but not at 10 weeks, given the pronounced chamber-and isoform-specific secondary changes in G protein and PLC␤ expression in ␣ q *52 mice at 10 weeks. We analyzed the effect of 2 agonists, endothelin-1 and carbachol, on total inositol phosphate formation as a measure of PLC activity (Figure 3 ). Endothelin-1 activates PLC in the heart by binding to endothelin A receptors and activating a pertussis toxin-insensitive G protein, presumably G q/11 (for a review, see Sugden and Bogoyevitch 18 ) . It is still a matter of debate which muscarinic receptor subtypes mediate the effect of carbachol on PLC activity. The heart contains predominantly M 2 muscarinic receptors that are coupled to pertussis toxin-sensitive G i /G o proteins. It may also contain M 1 and M 3 muscarinic receptors that are coupled to pertussis toxininsensitive G proteins. 19, 20 There are conflicting results regarding the pertussis toxin sensitivity of muscarinic stimulation of cardiac PLC activity. [21] [22] [23] The effect of G i /G o proteins Figure 3 . Chamber-specific differences in carbachol and endothelin-stimulated PLC activity in hearts of ␣ q *52 mice. Basal and agoniststimulated PLC activity in tissue pieces from left and right atria (top and middle, respectively) and free wall of right ventricle (bottom) from 2-week-old (left) and 10-week-old (right) ␣ q *52 and wild-type mice. Tissue pieces were incubated for 30 minutes in absence or presence of 100 mol/L carbachol (Carb) or 1 mol/L endothelin-1 (ET-1). In 2-week-old atria, 0.1 mol/L endothelin-was used in addition. Total inositol phosphate formation is expressed in cpm/mg tissue and represents meanϮSEM values. Similar results were obtained when cpm obtained were normalized to amount of protein in each tissue piece (data not shown). Because basal PLC activity was Ϸ5-fold lower in ventricles than in atrial appendages, scales of graphs are different. Number of mice studied in each condition is given in brackets.
on PLC is mediated by the ␤␥ subunits released on activation, whereas the ␣ q/11 subunits are largely responsible for mediation of the effect of pertussis toxin-insensitive G proteins (for a review, see Rhee and Bae 24 ). It is likely that in contrast to endothelin-1, more than one mechanism contributes to the effect of carbachol on PLC activity.
In accord with our hypothesis, at 2 weeks, a maximal dose of carbachol (100 mol/L) caused the same increment in PLC activity in ␣ q *52 as it did in wild-type hearts in all chambers tested (Figure 3, left) . Thus, carbachol-stimulated PLC activity was additive with the elevated basal activity. However, a high dose of endothelin-1 (1 mol/L) was additive in the right ventricle but not in the atria. Endothelin-1 causes a much more robust activation of PLC than does carbachol. In the atria of 2-week-old ␣ q *52 mice, the incremental response to a high dose of endothelin-1 (1 mol/L) was less than that in wild type, as if PLC activation were saturated. Consistent with this interpretation, a lower concentration of endothelin-1 (0.1 mol/L) produced similar increments over basal activity in wild-type and ␣ q *52 atria.
Consistent with the maturational decline in the amount of PLC␤ 1 and PLC␤ 3 in 10-week-old wild-type mice, basal PLC activity and responsiveness to both agonists tested declined with age (Figure 3, right) . In contrast to the approximately equal increment in carbachol-stimulated PLC activity over basal levels in wild-type and ␣ q *52 mice at 2 weeks, at 10 weeks, the carbachol-stimulated increase in activity was greater in ␣ q *52 than in wild-type mice in the right atrium. In the ventricles of ␣ q *52 mice, both carbachol and endothelin-1 responses were greater than in wild-type mice. The increased responsiveness of PLC to stimulation with 2 different agonists is presumably due to secondary increases in other signaling components, such as the rise in PLC␤ or endogenous ␣ q/11 , that may increase the efficiency of receptor coupling to PLC. As a result, ␣ q *52 mice may be more sensitive to hormones that are normally present in the heart, making them more susceptible to endogenous hypertrophic stimuli. The increased susceptibility may help sustain the pathological process.
DAG Formation
DAG, the other second messenger generated by PLC, is also produced by phospholipase D (PLD). The substrate for PLD, phosphatidyl choline, is much more abundant than the substrate for PLC, phosphatidyl inositol bisphosphate, so most of the DAG that accumulates in stimulated cells is derived from phosphatidyl choline (for a review, see Exton 25 ) and a rise in DAG in response to PLC␤ activation is not easily detectable. However, DAG activates some forms of PKC (including the PKC isoforms expressed in the heart; see later), and PKC, in turn, can activate PLD, thereby providing a mechanism for cross-talk and signal amplification between PLC and PLD in many cell types (for a review, see Exton 25 ), including the myocardium (for a review, see Eskildsen-Helmond et al 26 ). Although the mechanisms by which PKC activates PLD are not yet clearly defined, the positive feedback between these enzymes seems to allow a more prolonged rise in DAG and may enhance and prolong the activation of PKC.
In ventricles from ␣ q *52 mice, basal DAG levels were increased at 2 weeks (147Ϯ10% of wild type; nϭ4, Western blots loaded with particulate and soluble protein extracted from atrial and ventricular tissue, as well as ventricular cardiomyocytes, were probed with PKC isoform-specific antibodies. Atrial and ventricular tissue from both sides of the heart was combined except for 10-week atria (right side only). Chemiluminescent signals (such as shown in Figure 4 ) were quantified through densitometry and expressed as a percentage of age-matched wild-type controls (see Materials and Methods). Values are meanϮSEM from 2 to 4 atrial pools, 4 to 6 ventricles, and 2 ventricular myocyte pools.
*No statistical test was performed for the comparison between two atrial pools from 2-week-old ␣ q ‫25ء‬ and wild-type mice.
†PϽ0.05 (Student t test) compared with age-matched wild type.
PϽ0
.005) and at 10 weeks (184Ϯ12% of wild type; nϭ4; PϽ0.005). In contrast, there was a more modest rise in basal DAG levels in atria from ␣ q *52 mice (119Ϯ17% of wild type at 2 weeks and 157Ϯ8% of wild type at 10 weeks, 2 pools each; meanϮrange). In contrast to inositol phosphates, DAG was more elevated in ventricles than in atria, suggesting that the PLD pathway may play an important role in the perpetuation of ventricular pathology.
PKC
The activation of PKC can change the amount of PKC protein, induce translocation to the membrane, or both. 27 Three PKC isoforms expressed in the adult heart, PKC␣, PKC␦, and PKC⑀ (for reviews, see Pucéat and Vassort 28 and Steinberg et al 29 ) , showed a differential response to the chronic activation of PLC␤ in ␣ q *52 mice. We determined the relative amount of these PKC isoforms and their distribution between particulate and soluble fractions through Western blotting of hearts from 2-and 10-week-old ␣ q *52 and wild-type mice (Table 2 and Figure 4) . The results obtained for ventricular tissue were confirmed in isolated ventricular myocytes (Table 2) . Differences in mobility on SDS-PAGE presumably reflect different phosphorylation states (see, for example, Keranen et al 30 ) . At 2 weeks, PKC␣ and PKC␦ increased minimally in both atria and ventricles from ␣ q *52 mice. At 10 weeks, the rise in both PKC isoforms was more pronounced (Table 2) . Although there was no difference in the amount of membrane-bound PKC␣ or PKC␦ at 2 weeks, there was a significant increase in membranebound ventricular PKC␣ and atrial PKC␦ at 10 weeks ( Figure  4 ). The ratio of membrane-bound to soluble ventricular PKC␣ increased from 0.43Ϯ0.06 in wild type to 0.82Ϯ0.07 in ␣ q *52 (nϭ12 each, PϽ0.001); the ratio for atrial PKC␦ increased from 0.32Ϯ0.06 in wild type to 0.55Ϯ0.07 in ␣ q *52 (nϭ4 each, PϽ0.05). The total amount of PKC⑀ was decreased in ventricles, but not in atria, of 2-week-old ␣ q *52 mice (Table 2 ) without a change in the relative amount that was membrane bound (Figure 4 ). This decline was even more pronounced at 10 weeks. PKC⑀ seems to play a role in protection of the heart against damage from ischemia. 31, 32 A decrease in PKC⑀ in the ventricles of ␣ q *52 mice may therefore contribute to the worsening pathology. PKC⑀ is not downregulated but rather translocated in mice expressing unactivated ␣ q . 5 This difference may be due to a more pronounced activation of PLC with a constitutively active ␣ q compared with wild-type ␣ q . Our results suggest that the different PKC isoforms have different functions and that they are regulated by different mechanisms.
Conclusions
One of the advantages of transgenic mouse models is that the effects of the targeted overexpression of one protein can be studied in the context of the whole animal. In the present study, we demonstrate that multiple, long-lasting changes in signaling (including isoform-and chamber-specific changes) can be initiated by the transient expression of the transgenic protein and that additional secondary mechanisms continue to drive the pathology after the transgenic protein has been downregulated. It is possible that some of the changes observed at 10 weeks are a consequence rather than a cause of the cardiomyopathy. However, the fact that many of the changes begin early suggests that they do contribute to the development of the pathology. Our findings emphasize the plasticity of the cardiac response to the expression of an activated signaling molecule, as well as to pronounced differences in signaling response between atria and ventricles. Given the multitude and breadth of changes that are observed, it is likely that many different signaling pathways determine the hypertrophic response. Positive and negative feedback loops may also contribute. In delineation of the interplay of the various signaling events, their temporal sequence and the transcription factors that are involved will allow a better understanding of the network of these linked signaling functions and of their role in the development of cardiac hypertrophy. Chamber-and isoform-specific response of PKC isoforms in hearts of ␣ q *52 mice. Representative Western blots of PKC␣, PKC␦, and PKC⑀ in particulate (P) and soluble (S) fractions from atria (A) and ventricles (V) from 2-and 10-week-old ␣ q *52 and wild-type mice. Equal amounts of protein were loaded onto each lane. Tissue from both sides of heart was always combined except for 10-week-old atria (right atria only).
